Related Experiment Video
Updated: Aug 13, 2026
In vivo Dual Substrate Bioluminescent Imaging
Published on: October 11, 2011
In vivo imaging of tumor response to therapy using a dual-modality imaging strategy
Zdravka Medarova1, Wellington Pham, Young Kim
1Molecular Imaging Laboratory, MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
Abstract:
In vivo assessment of the outcome of cancer therapy is hampered by the paucity of imaging probes that target tumors specifically and noninvasively. The importance of such probes increases with the continuous development of chemotherapeutics and the necessity to evaluate their effectiveness in a clinical setting. We have recently reported on a dual-modality imaging probe specifically targeting the underglycosylated mucin-1 tumor-specific antigen (uMUC-1), which is one of the early hallmarks of tumorigenesis in a wide variety of tumors. This probe consists of crosslinked superparamagnetic iron oxide nanoparticles (CLIO) for MR imaging, modified with Cy5.5 dye (for near infrared optical fluorescence imaging (NIRF)), and has peptides (EPPT), specifically recognizing uMUC-1, attached to the nanoparticle's dextran coat. In the present study, we demonstrated that this probe could not only detect orthotopically implanted preclinical models of adenocarcinomas but could also track tumor response to chemotherapy in vivo in real time. Considering the high cost associated with the development and testing of new cancer therapeutics and the need for accurate, noninvasive assessment of their effectiveness, we believe that the developed probe represents a valuable research tool relevant to clinical discovery.
Insights
A novel dual-modality imaging probe targets the underglycosylated mucin-1 tumor-specific antigen (uMUC-1) for noninvasive cancer detection and real-time chemotherapy response tracking in preclinical models.
Area of Science:
- Biomedical Engineering
- Oncology Imaging
- Nanotechnology
Background:
- Effective cancer therapy assessment requires specific, noninvasive imaging probes.
- Underglycosylated mucin-1 (uMUC-1) is an early tumor hallmark targeted by novel agents.
- Current imaging limitations hinder real-time evaluation of chemotherapeutic efficacy.
Purpose of the Study:
- To develop and validate a dual-modality imaging probe for uMUC-1.
- To assess the probe's ability to detect tumors and monitor treatment response in vivo.
- To provide a valuable tool for preclinical cancer research and clinical discovery.
Main Methods:
- Constructed a dual-modality probe using crosslinked superparamagnetic iron oxide nanoparticles (CLIO) with Cy5.5 dye.
- Functionalized CLIO nanoparticles with EPPT peptides specific for uMUC-1.
- Evaluated probe performance in orthotopically implanted preclinical adenocarcinoma models.
Main Results:
- The dual-modality probe successfully detected orthotopically implanted tumors.
- The probe enabled real-time in vivo tracking of tumor response to chemotherapy.
- Demonstrated specificity for the underglycosylated mucin-1 tumor-specific antigen.
Conclusions:
- The developed uMUC-1 targeted dual-modality probe is effective for preclinical cancer detection.
- This imaging tool facilitates noninvasive, real-time assessment of chemotherapy effectiveness.
- The probe represents a significant advancement for cancer therapeutic research and clinical translation.
More Related Videos
12:09A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics
Published on: June 16, 2013
10:25A Dorsal Skinfold Window Chamber Tumor Mouse Model for Combined Intravital Microscopy and Magnetic Resonance Imaging in Translational Cancer Research
Published on: April 12, 2024